Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: Implications for Parkinson's disease

The pathogenic mechanisms underlying idiopathic Parkinson's disease (PD) remain enigmatic. Recent findings suggest that inflammatory processes are associated with several neurodegenerative disorders, including PD. Enhanced expression of the proinflammatory cytokine, tumor necrosis factor (TNF)‐α, has been found in association with glial cells in the substantia nigra of patients with PD. To determine the potential role for TNF‐α in PD, we examined the effects of the 1‐methyl‐4‐phenyl‐1,2,3,4‐tetrahydropyridine (MPTP), a dopaminergic neurotoxin that mimics some of the key features associated with PD, using transgenic mice lacking TNF receptors. Administration of MPTP to wild‐type (+/+) mice resulted in a time‐dependent expression of TNF‐α in striatum, which preceded the loss of dopaminergic markers and reactive gliosis. In contrast, transgenic mice carrying homozygous mutant alleles for both the TNF receptors (TNFR‐DKO), but not the individual receptors, were completely protected against the dopaminergic neurotoxicity of MPTP. The data indicate that the proinflammatory cytokine TNF‐α is an obligatory component of dopaminergic neurodegeneration. Moreover, because TNF‐α is synthesized predominantly by microglia and astrocytes, our findings implicate the participation of glial cells in MPTP‐induced neurotoxicity. Similar mechanisms may underlie the etiopathogenesis of PD.

[1]  A. O'Callaghan The astrocyte response to neural injury: a review and reconsideration of key features , 2002 .

[2]  J. O'Callaghan Measurement of Glial Fibrillary Acidic Protein , 2002, Current protocols in toxicology.

[3]  E. Hirsch,et al.  The inflammatory response in the Parkinson brain , 2001, Clinical Neuroscience Research.

[4]  R. Kaji,et al.  Tumor necrosis factor gene polymorphisms in patients with sporadic Parkinson's disease , 2001, Neuroscience Letters.

[5]  J. Cooper,et al.  Nitric oxide enhances MPP+ inhibition of complex I , 2001, FEBS letters.

[6]  Davide Franceschini,et al.  Kainic acid induces selective mitochondrial oxidative phosphorylation enzyme dysfunction in cerebellar granule neurons: protective effects of melatonin and GSH ethyl ester , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  M. Vila,et al.  The role of glial cells in Parkinson's disease , 2001, Current opinion in neurology.

[8]  A. Paetau,et al.  Evolution of Cerebral Tumor Necrosis Factor-&agr; Production During Human Ischemic Stroke , 2001, Stroke.

[9]  Michel Goedert,et al.  Alpha-synuclein and neurodegenerative diseases , 2001, Nature Reviews Neuroscience.

[10]  Jang-Soo Chun,et al.  Tumor Necrosis Factor-α Generates Reactive Oxygen Species via a Cytosolic Phospholipase A2-linked Cascade* , 2000, The Journal of Biological Chemistry.

[11]  David A. Martin,et al.  Inhibition of TNF‐α can attenuate or exacerbate excitotoxic injury in neonatal rat brain , 2000 .

[12]  J. O'Callaghan,et al.  Quantitative immunoblots of proteins resolved from brain homogenates: underestimation of specific protein concentration and of treatment effects. , 1999, Analytical biochemistry.

[13]  H. Ichinose,et al.  Increase in level of tumor necrosis factor (TNF)-α in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic l-DOPA on the TNF-α induction , 1999, Neuroscience Letters.

[14]  E. Hirsch,et al.  FcεRII/CD23 Is Expressed in Parkinson’s Disease and Induces, In Vitro, Production of Nitric Oxide and Tumor Necrosis Factor-α in Glial Cells , 1999, The Journal of Neuroscience.

[15]  P. Gebicke-haerter,et al.  Differential expression of inflammatory mediators in rat microglia cultured from different brain regions. , 1999, Brain research. Molecular brain research.

[16]  M. Boyd,et al.  Thiol Oxidation and Loss of Mitochondrial Complex I Precede Excitatory Amino Acid-Mediated Neurodegeneration , 1998, The Journal of Neuroscience.

[17]  J. Unger Glial reaction in aging and Alzheimer's disease , 1998, Microscopy research and technique.

[18]  P. Jenner,et al.  Understanding cell death in parkinson's disease , 1998, Annals of neurology.

[19]  W. Fiers,et al.  Cooperation of both TNF receptors in inducing apoptosis: involvement of the TNF receptor-associated factor binding domain of the TNF receptor 75. , 1998, Journal of immunology.

[20]  Romanelli,et al.  A new collection method for the evaluation of nasal mucus proteins , 1998, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[21]  M. Mass,et al.  The MAP Kinase Cascade Is Activated prior to the Induction of Gliosis in the 1‐Methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) Model of Dopaminergic Neurotoxicity , 1998, Annals of the New York Academy of Sciences.

[22]  J. O'Callaghan,et al.  The Impact of Gender and Estrogen on Striatal Dopaminergic Neurotoxicity , 1998, Annals of the New York Academy of Sciences.

[23]  Luigi Aloe,et al.  TNF-α expressed in the brain of transgenic mice lowers central tyroxine hydroxylase immunoreactivity and alters grooming behavior , 1997, Neuroscience Letters.

[24]  Kevin J. Tracey,et al.  Expression of TNF and TNF Receptors (p55 and p75) in the Rat Brain after Focal Cerebral Ischemia , 1997, Molecular medicine.

[25]  Y Agid,et al.  Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[26]  M. Boyd,et al.  Evidence for generation of oxidative stress in brain by MPTP: in vitro and in vivo studies in mice , 1997, Brain Research.

[27]  C. Olanow,et al.  Oxidative stress and the pathogenesis of Parkinson's disease , 1996, Neurology.

[28]  G. Kreutzberg,et al.  Signaling molecules and neuroglial activation in the injured central nervous system. , 1996, The Keio journal of medicine.

[29]  M. Mattson,et al.  Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors , 1996, Nature Medicine.

[30]  T. Nagatsu,et al.  Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease , 1996, Neuroscience Letters.

[31]  R. Ransohoff,et al.  Chemokines in immune-mediated inflammation of the central nervous system. , 1996, Cytokine & growth factor reviews.

[32]  G. Rondouin,et al.  Release of TNFα in the rat hippocampus following epileptic seizures and excitotoxic neuronal damage , 1996, Neuroreport.

[33]  K. Flanders,et al.  Transforming Growth Factor-β: Neuronal and Glial Expression in CNS Degenerative Diseases , 1995 .

[34]  W. Fiers,et al.  Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[35]  N. Hattori,et al.  Role of mitochondria in the etiology and pathogenesis of Parkinson's disease. , 1995, Biochimica et biophysica acta.

[36]  J. O'Callaghan,et al.  Quantitative aspects of drug and toxicant-induced astrogliosis , 1995, Neurochemistry International.

[37]  J. Gramsbergen,et al.  Regional and temporal profiles of calcium accumulation and glial fibrillary acidic protein levels in rat brain after systemic injection of kainic acid , 1994, Brain Research.

[38]  J. O'Callaghan,et al.  Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. , 1994, The Journal of pharmacology and experimental therapeutics.

[39]  I. Beletsky,et al.  Dual role of the p75 tumor necrosis factor (TNF) receptor in TNF cytotoxicity , 1994, The Journal of experimental medicine.

[40]  E. Hirsch,et al.  Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease , 1994, Neuroscience Letters.

[41]  V Balasingam,et al.  Reactive astrogliosis in the neonatal mouse brain and its modulation by cytokines , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[42]  Minoru Harada,et al.  Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients , 1994, Neuroscience Letters.

[43]  J. O'Callaghan Quantitative Features of Reactive Gliosis following Toxicant‐induced Damage of the CNS a , 1993, Annals of the New York Academy of Sciences.

[44]  D W Dickson,et al.  Cytokine production by human fetal microglia and astrocytes. Differential induction by lipopolysaccharide and IL-1 beta. , 1993, Journal of immunology.

[45]  J. Booss,et al.  Localization of TNFα and IL-1a immunoreactivities in striatal neurons after surgical injury to the hippocampus , 1993, Neuron.

[46]  J. Merrill Proinflammatory and Antiinflammatory Cytokines in Multiple Sclerosis and Central Nervous System Acquired Immunodeficiency Syndrome , 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[47]  C. Brosnan,et al.  Quantitative aspects of reactive gliosis: A review , 1992, Neurochemical Research.

[48]  K. Jellinger,et al.  Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease , 1992, Neuroscience Letters.

[49]  E. Benveniste Inflammatory cytokines within the central nervous system: sources, function, and mechanism of action. , 1992, The American journal of physiology.

[50]  W. Fiers,et al.  Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions. Evidence for the involvement of mitochondrial radical generation. , 1992, The Journal of biological chemistry.

[51]  L. Tartaglia,et al.  The two different receptors for tumor necrosis factor mediate distinct cellular responses. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[52]  L. Buée,et al.  Elevated circulating tumor necrosis factor levels in Alzheimer's disease , 1991, Neuroscience Letters.

[53]  M. Sharief,et al.  Association between Tumor Necrosis Factor-α and Disease Progression in Patients with Multiple Sclerosis , 1991 .

[54]  U. Schreiter-Gasser,et al.  Interleukin‐6 and α‐2‐macroglobulin indicate an acute‐phase state in Alzheimer's disease cortices , 1991, FEBS letters.

[55]  J. Merrill,et al.  HIV‐1, macrophages, glial cells, and cytokines in AIDS nervous system disease , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[56]  J. O'Callaghan Quantification of glial fibrillary acidic protein: comparison of slot-immunobinding assays with a novel sandwich ELISA. , 1991, Neurotoxicology and teratology.

[57]  R. Grossman,et al.  Elevation of tumor necrosis factor in head injury , 1990, Journal of Neuroimmunology.

[58]  J. Larrick,et al.  Cytotoxic mechanism of tumor necrosis factor‐α , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[59]  J. O'Callaghan,et al.  Characterization of the origins of astrocyte response to injury using the dopaminergic neurotoxicant, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine , 1990, Brain Research.

[60]  E. Benveniste,et al.  Tumor necrosis factor-alpha production by astrocytes. Induction by lipopolysaccharide, IFN-gamma, and IL-1 beta. , 1990, Journal of immunology.

[61]  C. Marsden,et al.  Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.

[62]  J. Parks,et al.  Abnormalities of the electron transport chain in idiopathic parkinson's disease , 1989, Annals of neurology.

[63]  M. Shin,et al.  Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[64]  J. Merrill,et al.  Tumor necrosis factor identified in multiple sclerosis brain , 1989, The Journal of experimental medicine.

[65]  T. Marunouchi,et al.  Production of tumor necrosis factor-alpha by microglia and astrocytes in culture , 1989, Brain Research.

[66]  A. H. V. Schapira,et al.  MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.

[67]  C. Marsden,et al.  Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease , 1989, Journal of neurochemistry.

[68]  C. Balaban,et al.  Trimethyltin-induced neuronal damage in the rat brain: Comparative studies using silver degeneration stains, immunocytochemistry and immunoassay for neuronotypic and gliotypic proteins , 1988, Neuroscience.

[69]  N. Sone,et al.  Effects of 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine and 1‐Methyl‐4‐Phenylpyridinium Ion on Activities of the Enzymes in the Electron Transport System in Mouse Brain , 1987, Journal of neurochemistry.

[70]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[71]  P. K. Smith,et al.  Measurement of protein using bicinchoninic acid. , 1985, Analytical biochemistry.

[72]  W. Nicklas,et al.  Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1985, Life sciences.

[73]  H. Towbin,et al.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[74]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[75]  A. Bousseau,et al.  Modulation of interleukin-1 and tumor necrosis factor expression by β-adrenergic agonists in mouse ameboid microglial cells , 2004, Experimental Brain Research.

[76]  H. Ichinose,et al.  Changes in cytokines and neurotrophins in Parkinson's disease. , 2000, Journal of neural transmission. Supplementum.

[77]  D. Pipeleers,et al.  Regulation of tumor necrosis factor-induced, mitochondria- and reactive oxygen species-dependent cell death by the electron flux through the electron transport chain complex I. , 1999, Antioxidants & redox signaling.

[78]  K. Tanaka,et al.  Increase in level of tumor necrosis factor (TNF)-alpha in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic L-DOPA on the TNF-alpha induction. , 1999, Neuroscience letters.

[79]  E. Hirsch,et al.  FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. , 1999, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[80]  T. Nagatsu,et al.  Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. , 1996, Neuroscience letters.

[81]  D. Ferrari,et al.  Activation of microglial cells by beta-amyloid protein and interferon-gamma. , 1995, Nature.

[82]  P. Riederer,et al.  Brain β2-microglobulin levels are elevated in the striatum in Parkinson's diseaselevels are elevated in the striatum in Parkinson's disease , 1995 .

[83]  J. W. Francis,et al.  Neuroglial responses to the dopaminergic neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse striatum. , 1995, Neurotoxicology and teratology.

[84]  P. Riederer,et al.  Brain beta 2-microglobulin levels are elevated in the striatum in Parkinson's disease. , 1995, Journal of neural transmission. Parkinson's disease and dementia section.

[85]  N. Hattori,et al.  Mitochondrial energy crisis in Parkinson's disease. , 1993, Advances in neurology.

[86]  J. Booss,et al.  Localization of TNF alpha and IL-1 alpha immunoreactivities in striatal neurons after surgical injury to the hippocampus. , 1993, Neuron.